With the successful launch of its Formulary brand RHO Phyto, Avicanna Launches a Medical Cannabis Program in Columbia.


The biopharmaceutical company Avicanna Inc. has been engaged in developing, manufacturing, and commercializing cannabinoid-based products that are plant derived. Along with this, it has announced its medical cannabis program in Colombia, under Formulaciones Magistrales, which is the compound pharmacy legislation, and Avicanna will supply its cannabinoid standardized formulary to the medical community. This program will include educating and training the medical community with a detailed program to support patients.

CEO of Avicanna Inc., Aras Azadian, is proud to be launching the program after two years of preparation in the medical community. He feels it will set the gold standard for medicines that are cannabinoid-based in Columbia. They expect to expand their product into other markets of Latin America. Cannabinoid preparations will need physician prescription and commercialized through business models like delivery to third party medical institutions, national pharmacies, and direct sales for patients throughout Columbia. The therapeutic areas that will benefit from RHO Phyto include neurological disorders as depression, anxiety, psychiatric indications such as PTSD, multiple sclerosis, Parkinson’s disease, epilepsy, and chronic pain.

RHO Phyto provides the first complete portfolio of branded dosage of its innovative cannabinoid preparations in the form of oil drops, topicals, capsules ranging from CBD to CBD-THC ratios, and sublingual sprays. Avicanna uses active pharmaceutical ingredients that have been brought from Santa Marta Golden Hemp S.A.S., which is mostly owned by Avicanna. Here, they extract cannabinoids from organic and cultivated plants. Avicanna’s Good Production Practices (GPP) completes the preparation of these products in their certified pharmacy lab in Bogota through Avicanna LATAM S.A.S., the subsidiary that they own. It is considered to be the first of its kind, certified for the preparation of cannabinoids. Avicanna medical team also manages patient support and education programs and operates them to ensure that quality of service is of Avicanna’s standards. The Avicanna patient-centered program will ensure that patients in Colombia will have therapeutic alternatives available to them. This will help improve their quality of life, manage their comorbidities, and solve some unmet medical requirements. The training program will include HCP health care practitioners, educational modules, training packages, certifications, real-world evidence trials, and medical symposia.